PHILADELPHIA, Aug. 3 /PRNewswire/ -- URL Pharma, a leading specialty pharmaceutical company, today announced it has acquired the assets of PharmPro, a division of Fluid Air, Inc. The facility, located in Aurora, Illinois, is FDA inspected and DEA (Drug Enforcement Agency) licensed. The acquisition expands the capacity and capabilities of URL Pharma's product development and manufacturing operations.
The 19,000 sq. ft. state-of-the-art facility includes fluid bed technology, enabling water and solvent coating processes critical to the development and manufacture of a wide array of modified release products. The acquisition also includes DuraGran(R), a proprietary platform technology that enables the efficient production of uniform, small granules in the development and manufacture of modified release dosage forms.
"This acquisition brings fluid bed technology in-house, enabling us to develop and manufacture a broad range of products for our pharmaceutical technology and brand pipelines," commented Richard H. Roberts, M.D., Ph.D., URL Pharma's President and Chief Executive Officer. "As part of this transaction, 17 former Fluid-Air employees, many with critical engineering expertise, will join URL Pharma and help integrate the new technology into our product development and manufacturing operations."
About URL Pharma
URL Pharma, Inc., headquartered in Philadelphia, Pennsylvania, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a profitable, technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medi
|SOURCE URL Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved